Source comparison
Hexarelin vs Other Growth Hormone Secretagogues: A Detailed Comparison
Hexarelin belongs to a family of growth hormone secretagogues that includes GHRP-2, GHRP-6, ipamorelin, and MK-677 (ibutamoren). Each compound in this class binds to GHS-R1a, but receptor affinity, signaling kinetics, and off-target effects differ meaningfully
This comparison does not assign a generated winner or score.
- Hexarelin belongs to a family of growth hormone secretagogues that includes GHRP-2, GHRP-6, ipamorelin, and MK-677 (ibutamoren). Each compound in this class binds to GHS-R1a, but receptor affinity, signaling kinetics, and off-target effects differ meaningfully. Understanding these differences is essential for selecting the appropriate secretagogue for specific research applications.
- Hexarelin
- High (Ki ~0.7 nM)
- 70–90% increase at 2 mcg/kg
- Rapid—40–60% reduction after 14 days daily dosing
- Minimal prolactin/cortisol elevation; cardioprotective GHS-R1a agonism
- 80–200 mcg/kg (preclinical); 1–2 mcg/kg IV (human)
- Highest potency for acute GH release; dual pituitary and hypothalamic activation; desensitization limits chronic use—best for pulsed protocols
- GHRP-6
- Moderate (Ki ~1.2 nM)
- 50–60% increase at 1 mcg/kg
- Moderate—20–30% reduction after 14 days
- Elevates prolactin by 30–50%; stimulates ghrelin appetite pathway
- 100 mcg/kg (preclinical); 1 mcg/kg IV (human)
- Reliable GH release with less desensitization than hexarelin; appetite stimulation complicates metabolic studies
- GHRP-2
- Moderate (Ki ~0.8 nM)
- 55–65% increase at 1 mcg/kg
- Low—minimal reduction over 14 days
- Moderate prolactin elevation (15–25%); low appetite stimulation
- Balanced potency and sustainability; lower desensitization than hexarelin; moderate prolactin rise requires consideration in endocrine studies
- Ipamorelin
- Moderate-low (Ki ~2.6 nM)
- 40–50% increase at 100 mcg/kg
- Very low—sustained response over 28 days
- No prolactin/cortisol elevation; highly selective for somatotrophs
- 100–300 mcg/kg (preclinical); 100–300 mcg SC (human)
- Most selective secretagogue—no off-target hormone effects; ideal for chronic dosing studies; lower peak GH than hexarelin but better long-term consistency
- MK-677 (Ibutamoren)
- High (Ki ~0.4 nM)
- 60–100% increase at 25 mg oral (human)
- Moderate—IGF-1 remains elevated but GH pulse amplitude declines 20–30% after 8 weeks
- Increases appetite significantly; water retention; fasting glucose elevation
- 10–25 mg oral daily (human)
- Only orally active GHS; sustained IGF-1 elevation over weeks; appetite and glucose effects limit metabolic research use; best for prolonged GH/IGF-1 axis activation studies
- Hexarelin's primary advantage is potency—it produces the highest acute GH release per unit dose, making it ideal for studies examining peak GH-dependent effects or short-duration interventions. The cardioprotective effects mediated by direct GHS-R1a activation in cardiac tissue are unique among the GHRPs—neither GHRP-2 nor ipamorelin demonstrates the same degree of infarct size reduction in ischemia models. However, the rapid desensitization profile means hexarelin is poorly suited for studies requiring daily dosing over weeks unless a pulsed protocol (2–3 times weekly) is used.
- Ipamorelin, by contrast, is the most sustainable secretagogue for chronic administration. It exhibits minimal desensitization, does not elevate prolactin or cortisol, and produces consistent GH pulses over 4–8 weeks of daily administration. Researchers studying long-term anabolic interventions, age-related GH decline, or muscle preservation during extended caloric restriction typically favor ipamorelin or Ipamorelin over hexarelin to avoid receptor downregulation. The tradeoff is lower peak GH—ipamorelin's GH pulse is approximately 40% lower than hexarelin's at equivalent molar doses.
- MK-677 (ibutamoren) occupies a distinct niche as the only orally bioavailable GHS, making it attractive for studies where daily subcutaneous injections are impractical. It sustains elevated IGF-1 levels for weeks, but the metabolic side effects—appetite stimulation, fasting glucose elevation by 5–10 mg/dL, and mild water retention—complicate its use in tightly controlled metabolic studies. MK-677 is best suited for research examining chronic GH/IGF-1 axis activation in aging models or muscle-wasting conditions where appetite stimulation is acceptable or even desirable.
- Our experience supporting research institutions has shown that combination protocols often outperform monotherapy. Pairing hexarelin with a GHRH analog like CJC 1295 NO DAC produces synergistic GH release because the two compounds activate different receptors—GHS-R1a (hexarelin) and GHRH-R (CJC-1295)—preventing receptor saturation and extending the duration of GH elevation. Similarly, alternating hexarelin with ipamorelin in weekly cycles allows researchers to leverage hexarelin's potency without incurring full desensitization.